Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 15 clinical trials
Featured trial
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

Bone marrow transplants (BMT) are one form of treatment for disorders of the blood, including leukemia. However, because the procedure is often associated with potentially life-threatening reactions, it is usually reserved for patients with serious illnesses under the age of 60 years old. One serious reaction complicating bone marrow transplants …

  • 569 views
  • 22 Dec, 2020
  • 1 location
Featured trial
Co-Infusion of Umbilical Cord Blood and Haploidentical CD34+ Cells Following Nonmyeloablative Conditioning as Treatment for Severe Aplastic Anemia and MDS Associated with Severe Neutropenia Refractory to Immunosuppressive Therapy

This study will evaluate the safety and effectiveness of treating patients with severe aplastic anemia (SAA) or myelopdysplastic syndrome (MDS) with both peripheral blood stem cells from a family member and umbilical cord blood stem cells from an unrelated donor. Patients with SAA or MDS for whom other treatments have …

myelodysplastic syndrome (mds)
aplastic anemia
anemia studies
myelodysplastic syndromes
anemia
  • 54 views
  • 22 Dec, 2020
  • 1 location
Featured trial
Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia

Background: Severe aplastic anemia is a rare and serious blood disorder. It happens when the immune system starts to attack the bone marrow cells. This causes the bone marrow to stop making red blood cells, platelets, and white blood cells. Standard treatment for this disease is horse-ATG and cyclosporine, which …

myelodysplastic syndrome (mds)
aplastic anemia
anemia studies
myelodysplastic syndromes
anemia
  • 172 views
  • 22 Dec, 2020
  • 1 location
Eltrombopag+hATG+CsA vs. hATG+CsA in Children With Severe AA

The analysis of our own clinical data suggests that majority of the hematologic responses observed after the course of h-ATG/CsA is partial, and about 10% tend to have cyclosporine dependence. The aim of the current study is to improve the rate and the quality of hematologic response as well as …

  • 45 views
  • 26 Feb, 2022
  • 1 location
Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)

Background Severe aplastic anemia (SAA) is a rare and serious blood disorder. It causes the immune system to turn against bone marrow cells. Standard treatment for SSA is a combination of 3 drugs (Cyclosporine [CsA], Eltrombopag [EPAG], and horse anti-thymocyte globulin [h-ATG]). Researchers want to see if starting people at …

antithymocyte globulin
reticulocyte count
eltrombopag
blood disorder
cyclosporine
  • 12 views
  • 26 Jul, 2022
  • 1 location
Oral Supplementation of 2'-Fucosyllactose in Allogeneic Bone Marrow Transplant Recipients

High dose chemotherapy and radiation used as preparative regimens in patients undergoing an allogeneic hematopoietic stem cell transplant (HSCT) disrupts intestinal homeostasis by damaging the intestinal epithelium and altering the intestinal microbiome. The investigators hypothesize that 2'-fucosyllactose (2FL) supplementation will be safe and tolerable and result in an increase in …

bone marrow transplant
graft versus host disease
allogeneic hematopoietic stem cell transplant
acute graft-versus-host disease
  • 0 views
  • 13 Jun, 2022
  • 1 location
Evaluate the Safety, Immunologic, and Virologic Responses of Donor Derived (DD) HIV-Specific T-cells (HST) in HIV-infected Individuals Following Allogeneic Bone Marrow Transplantation (alloRESIST)

targeting (NEET) therapy as a therapeutic strategy in HIV-infected individuals following Allogeneic Bone Marrow Transplantation (alloBMT).

  • 0 views
  • 15 Mar, 2022
  • 1 location
Resiliency in Older Adults Undergoing Bone Marrow Transplant (REBOUND)

transplant. This research is being done to determine if there are traits that make recipients more likely to bounce back following allogeneic bone marrow transplant (BMT).

hematologic malignancy
bone marrow procedure
cancer
chemotherapy regimen
bone marrow transplant
  • 0 views
  • 25 Mar, 2022
  • 1 location
Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)

This is an open-labelled and non-controlled Phase I/II clinical trial, evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after umbilical cord blood (UCB) transplantation in adult patients with hematologic malignancies. The dose limiting toxicity of HTLP injection will be evaluated using …

  • 0 views
  • 06 Nov, 2021
  • 2 locations
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

This research is being done to find out if an investigational drug, Nivolumab, can be safely administered after a "half-matched" (haplo) bone marrow transplant (BMT), and if the investigational drug will help to prevent or delay relapse or progression of sarcomas. In this study investigators will also be trying to …

kidney function tests
renal function
neutrophil count
metastasis
solid tumour
  • 12 views
  • 15 Jul, 2022
  • 3 locations